{
    "clinical_study": {
        "@rank": "151396", 
        "arm_group": [
            {
                "arm_group_label": "DC (dosing condition)", 
                "arm_group_type": "Experimental", 
                "description": "Escalation design."
            }, 
            {
                "arm_group_label": "Oral A", 
                "arm_group_type": "Experimental", 
                "description": "Escalation design. Planned end-dose is 5 mg."
            }, 
            {
                "arm_group_label": "Oral B", 
                "arm_group_type": "Experimental", 
                "description": "Escalation design. Planned end-dose is 10 mg."
            }, 
            {
                "arm_group_label": "Oral C", 
                "arm_group_type": "Experimental", 
                "description": "Escalation design. Planned end-dose is 20 mg."
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to investigate safety,\n      tolerability, pharmacokinetics (the exposure of the trial drug in the body) and\n      pharmacodynamics (the effect of the investigated drug on the body) of multiple doses of a\n      long acting GLP-1 analogue (NNC0113-0987) in healthy male subjects."
        }, 
        "brief_title": "Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Healthy"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male, who is considered to be generally healthy, based on the medical history,\n             physical examination and the results of vital signs, electrocardiogram (ECG) and\n             laboratory safety tests performed during the screening visit, as judged by the\n             investigator\n\n          -  Age 18-64 years (both inclusive) at the time of signing informed consent\n\n          -  BMI (body mass index) 20.0-29.9 kg/m^2 (both inclusive)\n\n        Exclusion Criteria:\n\n          -  History of, or presence of, cancer, diabetes or any clinically significant\n             cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal (GI),\n             endocrinological, haematological, dermatological, venereal, neurological, psychiatric\n             diseases or other major disorders, as judged by the investigator\n\n          -  Personal or family history of medullary thyroid carcinoma or multiple endocrine\n             neoplasia type 2\n\n          -  History of chronic pancreatitis or idiopathic acute pancreatitis\n\n          -  Use of prescription or non-prescription medicinal and herbal products (except routine\n             vitamins) within three weeks preceding the dosing period. Occasional use of\n             paracetamol or acetylsalicylic acid is permitted\n\n          -  Subject with previous GI surgery, except subjects that underwent uncomplicated\n             surgical procedures such as appendectomy, hernia surgery, biopsies, as well as\n             colonic and gastric endoscopy"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "82", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01967589", 
            "org_study_id": "NN9926-3950", 
            "secondary_id": [
                "2012-002893-30", 
                "U1111-1131-8724"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "DC (dosing condition)", 
                    "Oral A", 
                    "Oral B", 
                    "Oral C"
                ], 
                "description": "Once-daily doses for oral administration. Multiple doses with sequential dose increments over 10 weeks. Progression to next dose increment is based on a safety evaluation", 
                "intervention_name": "NNC0113-0987", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "DC (dosing condition)", 
                    "Oral A", 
                    "Oral B", 
                    "Oral C"
                ], 
                "description": "Once-daily doses for oral administration", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 27, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Harrow", 
                    "country": "United Kingdom", 
                    "zip": "HA1 3UJ"
                }
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "4", 
        "official_title": "Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of treatment emergent adverse events (TEAEs) recorded", 
            "safety_issue": "No", 
            "time_frame": "From the time of first dosing (Day 0) and until completion of the post-treatment follow-up visit (Day 83\u221297)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01967589"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the NNC0113-0987 plasma concentration curve", 
                "safety_issue": "No", 
                "time_frame": "During a dosing interval (0-24 hours) at steady state (Day 67; Day 68 and Day 69)"
            }, 
            {
                "measure": "Maximum observed NNC0113-0987 plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "During a dosing interval (0-24 hours) at steady state (Day 67; Day 68 and Day 69)"
            }, 
            {
                "measure": "Time to maximum observed NNC0113-0987 plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "During a dosing interval (0-24 hours) at steady state (Day 67; Day 68 and Day 69)"
            }, 
            {
                "measure": "Change in fasting plasma glucose (FPG)", 
                "safety_issue": "No", 
                "time_frame": "From baseline (Day 0, pre-dose) to after 10 weeks of treatment (Day 70)"
            }, 
            {
                "measure": "Change in HbA1C (glycosylated haemoglobin)", 
                "safety_issue": "No", 
                "time_frame": "From baseline (Day 0, pre-dose) to after 10 weeks of treatment (Day 70)"
            }, 
            {
                "measure": "Change in body weight", 
                "safety_issue": "No", 
                "time_frame": "From baseline (Day -1) to after 10 weeks of treatment (Day 70)"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}